# Regeneron Pharmaceuticals, Inc. (REGN) — Q3-2016 Earnings Results

**Report date:** 2016-11-04 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q3-2016

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 1.6%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.13 | N/A | +38.19% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management expressed confidence in their product pipeline and future growth. They acknowledged challenges but remain focused on innovation.

**Key quotes:**

> Management highlighted strong performance in key product areas.

> They emphasized ongoing investment in research and development.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron's strong EPS performance, beating expectations by over 38%, led to a positive stock reaction, with shares rising 1.6%. The company continues to focus on its product pipeline and innovation, which may support future growth. However, the lack of revenue data and guidance leaves some uncertainty for investors.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q3-2016_